Renal and neurohormonal changes following simultaneous administration of systemic vasoconstrictors and dopamine or prostacyclin in cirrhotic patients with hepatorenal syndrome

J Hepatol. 1996 Dec;25(6):916-23. doi: 10.1016/s0168-8278(96)80297-2.


Background/aims: Intravenous ornipressin in cirrhotic patients with hepatorenal syndrome causes marked improvement of systemic hemodynamics and suppression of plasma renin and norepinephrine but only moderate improvement of renal function. This study was designed to investigate whether these beneficial effects could be enhanced by the simultaneous administration of dopamine. The renal effects of the i.v. infusion of norepinephrine plus prostacyclin in patients with hepatorenal syndrome were also assessed.

Methods: Renal plasma flow, glomerular filtration rate, free water clearance, sodium excretion and the plasma levels of renin and norepinephrine were measured in baseline conditions and during the administration of ornipressin (6 i.u./h) and ornipressin (6 i.u./h) plus dopamine (2 micrograms/kg.min) in nine patients with hepatorenal syndrome. Five additional patients with hepatorenal syndrome were studied prior to and following the administration of norepinephrine (0.45 +/- 0.1 microgram/kg.min) and norepinephrine (0.85 +/- 0.2 microgram/kg.min) plus prostacyclin (5 ng/kg.min).

Results: Despite a significant increase in arterial pressure and marked suppression of plasma renin activity during ornipressin and ornipressin plus dopamine administration, no significant improvement in renal function was observed. Norepinephrine and norepinephrine plus prostacyclin also failed to increase renal perfusion and glomerular filtration rate.

Conclusions: The combined administration of systemic vasoconstrictors (ornipressin or norepinephrine) and vasodilators (dopamine or prostacyclin), at the doses used in the current study and for a short period of time, does not improve renal function in cirrhotic patients with hepatorenal syndrome. The current study does not confirm a potential role for ornipressin in the treatment of hepatorenal syndrome.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antihypertensive Agents / administration & dosage*
  • Antihypertensive Agents / therapeutic use
  • Blood Pressure / drug effects
  • Dopamine / administration & dosage*
  • Dopamine / therapeutic use
  • Drug Therapy, Combination
  • Epoprostenol / administration & dosage*
  • Epoprostenol / therapeutic use
  • Female
  • Glomerular Filtration Rate / drug effects
  • Hepatorenal Syndrome / blood
  • Hepatorenal Syndrome / drug therapy
  • Hepatorenal Syndrome / physiopathology*
  • Humans
  • Infusions, Intravenous
  • Kidney / drug effects
  • Kidney / physiology*
  • Liver Cirrhosis / blood
  • Liver Cirrhosis / drug therapy
  • Liver Cirrhosis / physiopathology*
  • Male
  • Middle Aged
  • Norepinephrine / administration & dosage
  • Norepinephrine / blood*
  • Ornipressin / administration & dosage*
  • Ornipressin / therapeutic use
  • Renal Plasma Flow / drug effects
  • Renin / blood
  • Sodium / urine
  • Treatment Outcome
  • Vasoconstrictor Agents / administration & dosage*
  • Vasoconstrictor Agents / therapeutic use


  • Antihypertensive Agents
  • Vasoconstrictor Agents
  • Ornipressin
  • Sodium
  • Epoprostenol
  • Renin
  • Dopamine
  • Norepinephrine